fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Non Banking Mergers & Acquisitions

Amgen’s acquisition of Horizon Therapeutics for $27.8 billion marks the largest healthcare deal of 2022

The deal becomes the biggest since AstraZeneca bought Alexion Pharmaceuticals for $39 billion in the year 2020

Riya Thomas by Riya Thomas
December 13, 2022
in Mergers & Acquisitions, Healthcare, The Global Economics, Top Stories
Reading Time: 3 mins read
0
Amgen’s acquisition of Horizon Therapeutics for $27.8 marks the largest healthcare deal of 2022

Amgen’s acquisition of Horizon Therapeutics for $27.8 marks the largest healthcare deal of 2022

31
SHARES
172
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

Amgen secured a bridge fund to facilitate the purchase joining AT&T and Broadcom and will fund the purchase with a bridge credit facility from Bank of America and Citigroup

Amgen set to buy Horizon Therapeutics for $27.8 billion in its largest-ever acquisition arranging a $28.5 billion bridge credit facility. The company will pay $116.50 per share in cash for a premium of about 48%. Amgen is the maker of the Enbrel treatment for autoimmune ailments like ankylosing spondylitis and psoriasis. The therapies are used and tested in various indications after reaching the market.

Horizon receives most of its sales from Tepezza, which is the treatment for the autoimmune condition called thyroid eye disease. Amgen recently acquired another drug company ChemoCentryx. The deal becomes the biggest since AstraZeneca bought Alexion Pharmaceuticals for $39 billion in the year 2020. Amgen is struggling with the threat of impending diminished revenue as some of the firm’s product faces a loss of patent protection in the advancing years.

Amgen secured a bridge fund to facilitate the purchase joining AT&T and Broadcom and will fund the purchase with a bridge credit facility from Bank of America and  Citigroup. Bridge loans provided by banks are usually restored with permanent financing in the bond market, which is then sold to institutional investors. This deal would be the second time this year that the banks have come together to fund and advise a large deal, following their work on Philip Morris International’s acquisition of Swedish Match. Amgen had almost $11.5 billion in cash and equivalents by the end of the third quarter.

A Strategic Deal

The deal is undoubtedly expensive for Amgen, but it would provide a potential sales boost to Amgen. Horizon will help to fill the revenue losses the company incurred in recent years and the acquisition will strengthen the firm’s various areas including development, marketing, and the manufacturing of biologic drugs. Horizon’s acquisition was not without any competition as several leading companies had eyed the Dublin-based biotech research firm, but the price shot up. Johnson & Johnson and Sanofi SA were also in the bid to buy the company.

Sanofi had mentioned that the transaction prices exceeded their value creation criteria. This is also because of the increased expectation of Horizon’s portfolio. Horizon recently raised the sales forecast of Tepezza and is expected to reach the peak of annual sales, bringing in more than $4 billion due to increased demand in the US.

The sales of Krystexxa, the gout drug are also increasing and have an expected value of $1.5 billion.  “We’ve admired Horizon’s success for some time, and we’ve studied their business closely through time as well, and when presented with this opportunity, we were prepared to move quickly,” stated Amgen’s Chief Executive Officer.

Amgen’s biomanufacturing life-cycle management and immensity knowledge could help the company achieve more revenue earnings and potentially increase them. Since most of Horizon’s products are approved in the United States, Amgen could receive long-term growth and development. The company also informs that the purchase of Horizon is expected to increase earnings per share, on a non-GAAP basis expecting to start in the year 2024. It foresees $500 million in annual pre-tax cost savings by the end of the third fiscal year after the conclusion.

Thousand Oaks, California-based Amgen has far surpassed its rivals this year, with its stock rising 24% through Friday to a market value reaching $149 billion. The previous month, Amgen reported revenue and profit that exceeded analyst estimates as drugs had record quarterly sales and kept operating expenses in order. Horizon shares gained as much as 15% to $112, their highest intraday level since April. Amgen’s shares fell 1.5%.

Via: short URL
Tags: Amgenbiologic drugsHorizon Therapeutics
Riya Thomas

Riya Thomas

Related Posts

A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit
Ultility

A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit

by Riya Thomas
February 1, 2023
investment
The Global Economics

Adani Enterprises To Get $400 mn From Abu Dhabi’s IHC

by Marifur Rahman
January 31, 2023
Oil storage tank
Islamic

Saudi Arabia Lowers Crude Prices For Asia, Not For the US

by Anuj Singh
January 31, 2023
Adani Group shares plunged, resulting in the erasure of $72 billion after three-day selloffs
Funds

72 Billion Wiped Out: Adani Group Shares Plunge After Three-Day Selloffs

by Riya Thomas
January 30, 2023
A girl using a smartphone
Digital

China’s 2022 Smartphone Sales Plunge to the Lowest Level in a Decade

by Khushboo Pandey
January 30, 2023
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

Lebanon currency devaluation

Lebanon to Devalue Its Currency By 90%

February 1, 2023
A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit

A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit

February 1, 2023
China To Boost Oil Demand By Up To 500,000 BPD PC: Reuters

Oil Cools Off on a Weak Dollar

February 1, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Receive the latest news

Subscribe To Our Weekly Newsletter

Get notified about new articles, delivered right into your email inbox.

-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version